ARGX-119
Cancer
Phase 1Active
Key Facts
About Argenx
argenx is a Dutch-American biotechnology company focused on developing innovative antibody therapies for patients suffering from severe autoimmune diseases and cancer. Founded in 2008, the company has successfully commercialized VYVGART® (efgartigimod) for myasthenia gravis and is advancing multiple programs leveraging its proprietary SIMPLE Antibody™ platform. With operations in the Netherlands, Belgium, and the United States, argenx has established itself as a leader in FcRn antagonist therapies and immunology drug development.
View full company profileOther Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| Targeted Oncology Therapies | BioNTech | Phase 1/2 |
| Oncology Program | Shionogi | Clinical |
| Bmab (Bevacizumab) | Biocon | Approved |
| Ciforadenant (CPI-444) | Corvus Pharmaceuticals | Phase 1/2 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| XmAb 13676 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |
| PB272 (neratinib, intravenous) | Puma Biotechnology | Not Disclosed |